Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: Selective effects on mutant cells and improvements in measures of disease severity

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 6891-6900

  Liu, Phillip C C ^a   Caulder, Eian ^a   Li, Jun ^a   Waeltz, Paul ^a   Margulis, Alex ^a   Wynn, Richard ^a   Becker Pasha, Mary ^a   Li, Yanlong ^a   Crowgey, Erin ^a   Hollis, Gregory ^a   Haley, Patrick ^a   Sparks, Richard B ^a   Combs, Andrew P ^a   Rodgers, James D ^a   Burn, Timothy C ^a   Vaddi, Kris ^a   Fridman, Jordan S ^a  

^a Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INCB 16562; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG INHIBITION; GENE MUTATION; MOUSE; MYELOPROLIFERATIVE DISORDER; NEOPLASM; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; JANUS KINASE 1; JANUS KINASE 2; KINETICS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; POLYCYTHEMIA VERA;

EID: 72549116877     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1298     Document Type: Article

References (50)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-2466
2. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology (Am Soc Hematol Educ Program) 2006;240-245
3. Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 2007;117:2033-2035 (Pubitemid 47219542)
4. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652 (Pubitemid 34815868)
5. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-3539 (Pubitemid 34534519)
6. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007;6:550-566
7. Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 1974;290:1382.
8. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008;22:23-30.
9. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061 (Pubitemid 40386783)
10. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-1148 (Pubitemid 40663494)
11. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352: 1779-1790 (Pubitemid 40570926)
12. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397 (Pubitemid 40544655)
13. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005;102:18962-18967
14. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006;66:11156-11165
15. Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia veralike disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274-4281
16. Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2007; 22:1-9.
17. Lacout C, Pisani DF, Tul liez M, et al . JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108: 1652-1660
18. Funakoshi-Tago M, Tago K, Sumi K, et al. The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice. J Biol Chem 2009;284:12680-12690
19. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009;106:9414-9418
20. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelo-fibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
21. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468 (Pubitemid 46193073)
22. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-423 (Pubitemid 37013211)
23. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
24. Xiang Z, Zhao Y, Mitaksov V, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111: 4809-4812
25. Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008;205:751-758 (Pubitemid 351549874)
26. Jeong EG, Kim MS, Nam HK, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008; 14:3716-3721
27. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2008;457:200-204
28. Ho CL, Lasho TL, Butterfield JH, Tefferi A. Global cytokine analysis in myeloproliferative disorders. Leuk Res 2007;31:1389-1392 (Pubitemid 47212423)
29. Hermouet S, Godard A, Pineau D, et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine 2002;20:178-183 (Pubitemid 37163469)
30. Tefferi A. Pathogenesis of myelofibrosis with myeloidmetaplasia. J Clin Oncol 2005;23:8520-8580
31. Bedner E, Smolewski P, Amstad P, Darzynkiewicz Z. Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with dna fragmentation. Exp Cell Res 2000;259:308-313 (Pubitemid 30681536)
32. Dai CH, Krantz SB, Green WF, Gilbert HS. Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol 1994;86:12-21.
33. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15:146-155 (Pubitemid 40332537)
34. Pradhan A, Lambert QT, Reuther GW. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc Natl Acad Sci U S A 2007;104:18502-18507 (Pubitemid 350210726)
35. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007;21:1658-1668 (Pubitemid 47086756)
36. Weinstein IB.Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002;297:63-64
37. Tefferi A, Kantarjian HM, Pardanani AD, et al. The clinical phenotype of myelofibrosis encom-passes a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2. ASH Annual Meeting Abstracts 2008;112:2804.
38. Fridman JS, Caulder E, Wen X et al. Small molecule inhibitors of JAK1/2 improve physiological and functional measures of cancer-associated cachexia. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO; 2009, Abstract nr 2848.
39. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93:373-383
40. Huang HM, Lin YL, Chen CH, Chang TW. Simultaneous activation of JAK1 and JAK2 confers IL-3 independent growth on Ba/F3 pro-B cells. J Cell Biochem 2005;96:361-375
41. Jedidi A, Marty C, Oligo C, et al. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 2009;114:1842-1851
42. Verstovsek S, Kantarjian H, Pardanani A, et al. The JAK Inhibitor, INCB081424, demostrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/ essential thrombocythemia myelofibrosis (post PV/ET-MF). ASH Annual Meeting Abstracts 2008; 112:1762.
43. Mesa RA, Schwager S, Radia D, et al. Assessment and monitoring of constitutional symptoms in patients with myelofibrosis: a proposed new instrument the Myelofibrosis Symptom Assessment Form (MFSAF). ASH Annual Meeting Abstracts 2008;112:1754.
44. Walz C, Cross NC, Van Etten RA, Reiter A. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia 2008;22:1320-1334
45. Hexner EO, Serdikoff C, Jan M, et al. Lestaur-tinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111:5663-5671
46. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-320
47. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302: 875-878
48. Lasho TL, Tefferi A, Hood JD, et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008;22:1790-1792
49. Verstovsek S, Pardanani AD, Shah NP, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstracts 2007;110:553.
50. Verstovsek S, Kantarjian H, Pardanani A, et al. INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). ASH Annual Meeting Abstracts 2007;110:558.